|
1
|
Feuer EJ, Wun LM, Boring CC, Flanders WD,
Timmel MJ and Tong T: The life time risk of developing breast
cancer. J Natl Cancer Inst. 85:892–897. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Valero V and Hortobagyi GN: Are
anthracycline-taxane regimens the new standard of care in the
treatment of metastatic breast cancer? J Clin Oncol. 21:959–962.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wahl AF, Donaldson KL, Fairchild C, Lee
FY, Foster SA, Demers GW and Galloway DA: Loss of normal p53
function confers sensitization to Taxol by increasing G2/M arrest
and apoptosis. Nat Med. 2:72–79. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Haldar S, Chintapalli J and Croce CM:
Taxol induces bcl-2 phosphorylation and death of prostate cancer
cells. Cancer Res. 56:1253–1255. 1996.PubMed/NCBI
|
|
5
|
Yu D, Liu B, Tan M, Li J, Wang SS and Hung
MC: Overexpression of c-erbB-2/neu in breast cancer cells confers
increased resistance to Taxol via mdr-1-independent mechanisms.
Oncogene. 13:1359–1365. 1996.PubMed/NCBI
|
|
6
|
Pianetti S, Arsura M, Romieu-Mourez R,
Coffey RJ and Sonenshein GE: Her-2/neu overexpression induces
NF-kappaB via a PI3-kinase/Akt pathway involving calpain-mediated
degradation of IkappaB-alpha that can be inhibited by the tumor
suppressor PTEN. Oncogene. 20:1287–1299. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Aggarwal BB, Shishodia S, Takada Y,
Banerjee S, Newman RA, Bueso-Ramos CE and Price JE: Curcumin
suppresses the paclitaxel-induced nuclear factor-kappaB pathway in
breast cancer cells and inhibits lung metastasis of human breast
cancer in nude mice. Clin Cancer Res. 11:7490–7498. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Pledgie-Tracy A, Sobolewski MD and
Davidson NE: Sulforaphane induces cell type-specific apoptosis in
human breast cancer cell lines. Mol Cancer Ther. 6:1013–1021. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cornblatt B, Ye L, Dinkova-Kostova A, Erb
M, Fahey JW, Singh NK, Chen MS, Stierer T, Garrett-Mayer E, Argani
P, et al: Preclinical and clinical evaluation of sulforaphane for
chemoprevention in the breast. Carcinogenesis. 28:1485–1490. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jackson SJ and Singletary KW: Sulforaphane
inhibits human MCF-7 mammary cancer cell mitotic progression and
tubulin polymerization. J Nutr. 134:2229–2236. 2004.PubMed/NCBI
|
|
11
|
Myzak MC, Hardin K, Wang R, Dashwood RH
and Ho E: Sulforaphane inhibits histone deacetylase activity in
BPH-1, LnCap and PC-3 prostate epithelial cells. Carcinogenesis.
27:811–819. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Jackson SJ and Singletary KW:
Sulforaphane: A naturally occurring mammary carcinoma mitotic
inhibitor, which disrupts tubulin polymerization. Carcinogenesis.
25:219–227. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Benedict AL, Mountney A, Hurtado A, Bryan
KE, Schnaar RL, Dinkova-Kostova AT and Talalay P: Neuroprotective
effects of sulforaphane after contusive spinal cord injury. J
Neurotrauma. 29:2576–2586. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ozes ON, Mayo LD, Gustin JA, Pfeffer SR,
Pfeffer LM and Donner DB: NF-kappaB activation by tumour necrosis
factor requires the Akt serine-threonine kinase. Nature. 401:82–85.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang CY, Cusack JC Jr, Liu R and Baldwin
AS Jr: Control of inducible chemoresistance: Enhanced anti-tumor
therapy through increased apoptosis by inhibition of NF-kappaB. Nat
Med. 5:412–417. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang CY, Mayo MW, Korneluk RG, Goeddel DV
and Baldwin AS Jr: NF-kappaB antiapoptosis: Induction of TRAF1 and
TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation.
Science. 281:1680–1683. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mabuchi S, Ohmichi M, Kimura A, Hisamoto
K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E,
Nakatsuji Y, et al: Inhibition of phosphorylation of BAD and Raf-1
by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol
Chem. 277:33490–33500. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hu L, Hofmann J, Lu Y, Mills GB and Jaffe
RB: Inhibition of phosphatidylinositol 3′-kinase increases efficacy
of paclitaxel in in vitro and in vivo ovarian cancer models. Cancer
Res. 62:1087–1092. 2002.PubMed/NCBI
|
|
19
|
MacKeigan JP, Taxman DJ, Hunter D, Earp HS
III, Graves LM and Ting JP: Inactivation of the antiapoptotic
phosphatidylinositol 3-kinase-Akt pathway by the combined treatment
of taxol and mitogen-activated protein kinase kinase inhibition.
Clin Cancer Res. 8:2091–2099. 2002.PubMed/NCBI
|
|
20
|
Deeb D, Gao X, Dulchavsky SA and Gautam
SC: CDDO-Me inhibits proliferation, induces apoptosis,
down-regulates Akt, mTOR, NF-kappaB and NF-kappaB-regulated
antiapoptotic and proangiogenic proteins in TRAMP prostate cancer
cells. J Exp Ther Oncol. 7:31–39. 2008.PubMed/NCBI
|
|
21
|
Kim JH, Gupta SC, Park B, Yadav VR and
Aggarwal BB: Turmeric (Curcuma longa) inhibits inflammatory nuclear
factor (NF)-κB and NF-κB-regulated gene products and induces death
receptors leading to suppressed proliferation, induced
chemosensitization, and suppressed osteoclastogenesis. Mol Nutr
Food Res. 56:454–465. 2012. View Article : Google Scholar : PubMed/NCBI
|
